Samrat Pharmachem Q1 Net Profit at ₹0.88 Cr; Swings to Profit from ₹0.23 Cr Loss YoY
Samrat Pharmachem reported a standalone revenue from operations of ₹79.76 crore for Q1 ended June 30, 2026, marking a 5.4% YoY increase and 11.1% QoQ growth. The company swung back into profitability with a net profit of ₹0.88 crore compared to a net loss of ₹0.23 crore in Q1 FY26 and a net loss of ₹2.04 crore in Q4 FY26. Profit before tax stood at ₹1.59 crore, recovering from a PBT loss of ₹1.87 crore in the preceding quarter. Diluted EPS for the quarter came in at ₹2.84 compared to ₹(0.74) YoY.
உச்சம் நம்பிக்கை
என்ன மாறியதுSamrat Pharmachem returned to profitability in Q1 after reporting consecutive quarterly losses throughout FY26.
ஏன் இது முக்கியம்The operational turnaround helps reverse the ₹3.0 crore full-year loss of FY26 and provides margin relief for the micro-cap chemical manufacturer.
Revenue from operations: ₹7,976.10 லட்சம்Profit before tax: ₹158.53 லட்சம்Net Profit (PAT): ₹87.60 லட்சம்EPS: ₹2.84
📅 குறுகிய காலம்Likely to be viewed positively in the near term as earnings rebound back into positive territory after four loss-making quarters.
📈 நீண்ட காலம்Structural sustainability relies on expanding operating margins in its single segment of pharmaceutical chemicals, where raw material costs remain high relative to revenue.
⚠ அபாய எச்சரிக்கைகள்
- High sensitivity to raw material prices (cost of materials consumed remains ~98% of revenue)
- Historical earnings and margin volatility
👀 கவனிக்க வேண்டியவை
Monitor whether the operational profitability and gross margin recovery can be sustained across subsequent quarters amid raw material price fluctuations.
